BAMF
ALXN

BI Asset Management Fondsmaeglerselskab’s Alexion Pharmaceuticals ALXN Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-53,286
Closed -$6.1M – 506
2020
Q3 		$6.1M Sell
53,286
-8,110
-13% -$875K 0.28% 84
2020
Q2 		$6.89M Buy
61,396
+149
+0.2% +$15.8K 0.35% 69
2020
Q1 		$5.5M Buy
61,247
+4,574
+8% +$449K 0.33% 55
2019
Q4 		$6.13M Buy
+56,673
New +$6.06M 0.29% 59

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's ALXN Position: Q4 2020 in Review

BI Asset Management Fondsmaeglerselskab sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 53,286 shares — an estimated $6.1M sold.

BI Asset Management Fondsmaeglerselskab first reported a position in ALXN in Q4 2019 and held it in 4 quarters. The position peaked at $6.89M in Q2 2020. 825 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 53,286 Alexion Pharmaceuticals shares in Q4 2020, an estimated $6.1M.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • BI Asset Management Fondsmaeglerselskab's Alexion Pharmaceuticals position peaked at $6.89M in Q2 2020.
  • 825 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q4 2020, filed 12 Feb 2021.